---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005659"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:03:47.833213+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO licenses RGX-121/RGX-111 to Nippon Shinyaku for $110M upfront, up to $700M milestones

## Summary
- Upfront $110M, milestones up to $700M ($40M dev/reg, $660M sales), plus double-digit royalties on net sales in U.S. and Asia.
- REGENXBIO retains 100% of proceeds from RGX-121 Priority Review Voucher; rolling BLA submitted, potential FDA approval late 2025.
- Nippon Shinyaku to commercialize in Licensed Territory (U.S., Asia); REGENXBIO leads manufacturing and retains rest-of-world rights.
- RGX-111 for MPS I (Hurler) also included; Phase 1/2 results promising. Deal expected to close by end of Q1 2025.

## SEC filing metadata
- accession: 0001193125-25-005659
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312525005659/0001193125-25-005659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312525005659/d868307d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005659
- JSON: https://secwatch.observer/filing/0001193125-25-005659.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.